Aurinia Pharmaceuticals Inc. (AUPH) Stock Rating Reaffirmed by HC Wainwright
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Wednesday. They presently have a $10.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 96.08% from the company’s current price.
Several other brokerages have also recently weighed in on AUPH. FBR & Co reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. Canaccord Genuity set a $10.00 price target on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 5th. Finally, Leerink Swann reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Aurinia Pharmaceuticals in a research report on Monday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 5.10 on Wednesday. The stock has a 50 day moving average price of $2.38 and a 200 day moving average price of $2.77. The firm’s market cap is $179.96 million. Aurinia Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $5.69.
An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp boosted its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned 0.29% of Aurinia Pharmaceuticals worth $283,000 at the end of the most recent quarter. Institutional investors own 20.04% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.